白细胞介素-1受体药理阻断抑制早产胎羊中大肠杆菌脂多糖诱导的神经炎症
在妊娠105天单胎母羊中随机分组,经羊膜腔注射大肠杆菌脂多糖后给予rytvela或阿那白滞素。两种药物均显著减轻脑室周围白质损伤、小胶质细胞激活和组织学绒毛膜羊膜炎;阿那白滞素还抑制胎肺髓过氧化物酶活性,但与代谢性酸血症和胎血浆胰岛素样生长因子-1降低相关。
要点
- 羊膜腔注射rytvela或阿那白滞素均显著预防脂多糖诱导的胎脑炎症和绒毛膜羊膜炎。
- 阿那白滞素额外抑制胎肺髓过氧化物酶活性,但与代谢性酸血症和胎血浆胰岛素样生长因子-1降低相关。
- 研究为早产胎羊模型,两种药物对胎脑保护作用需进一步研究。
核心结论
- 羊膜腔注射rytvela或阿那白滞素显著抑制暴露于羊膜腔脂多糖的早产胎羊的胎脑炎症和绒毛膜羊膜炎。
- 阿那白滞素治疗与对发育中胎儿的潜在负面影响相关。
研究设计与样本
- 研究为早产胎羊模型,妊娠105天单胎母羊随机分为4组:生理盐水组(n=12)、脂多糖组(n=11)、脂多糖+rytvela组(n=10)、脂多糖+阿那白滞素组(n=12)。
- 脂多糖剂量为10 mg,rytvela剂量为2.5 mg,阿那白滞素剂量为100 mg,均于0小时和24小时经羊膜腔注射。
- 主要结局为评估阿那白滞素和rytvela在脂多糖诱导宫内炎症背景下的胎脑保护作用;次要结局为评估对胎儿和宫内炎症的保护作用。
主要发现
- 羊膜腔注射脂多糖导致早产胎羊胎肺、胎脑炎症和绒毛膜羊膜炎。
- 与脂多糖暴露下仅用生理盐水治疗相比,羊膜腔给予rytvela和阿那白滞素均显著预防脑室周围白质损伤、小胶质细胞激活和组织学绒毛膜羊膜炎。
- 阿那白滞素额外抑制胎肺髓过氧化物酶活性,但其使用与分娩时代谢性酸血症和胎血浆胰岛素样生长因子-1水平降低相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Intraamniotic inflammation is associated with preterm birth, especially in cases occurring before 32 weeks' gestation, and is causally linked with an increased risk for neonatal mortality and morbidity. Targeted anti-inflammatory interventions may assist in improving the outcomes for pregnancies impacted by intrauterine inflammation. Interleukin-1 is a central upstream mediator of inflammation. Accordingly, interleukin-1 is a promising candidate target for intervention therapies and has been targeted previously using the interleukin-1 receptor antagonist, anakinra. Recent studies have shown that the novel, noncompetitive, allosteric interleukin-1 receptor inhibitor, rytvela, partially resolved inflammation associated with preterm birth and fetal injury. In this study, we used a preterm sheep model of chorioamnionitis to investigate the anti-inflammatory efficacy of rytvela and anakinra, administered in the amniotic fluid in the setting of intraamniotic Escherichia coli lipopolysaccharide exposure. OBJECTIVE: We hypothesized that both rytvela and anakinra would reduce lipopolysaccharide-induced intrauterine inflammation and protect the fetal brain. STUDY DESIGN: Ewes with a singleton fetus at 105 days of gestation (term is ∼150 days) were randomized to one of the following groups: (1) intraamniotic injections of 2 mL saline at time=0 and time=24 hours as a negative control group (saline group, n=12); (2) intraamniotic injection of 10 mg Escherichia coli lipopolysaccharide in 2 mL saline and intraamniotic injections of 2 mL saline at time=0 hours and time=24 hours as an inflammation positive control group (lipopolysaccharide group, n=11); (3) intraamniotic injection of Escherichia coli lipopolysaccharide in 2 mL saline and intraamniotic injections of 2.5 mg rytvela at time=0 hours and time=24 hours to test the anti-inflammatory efficacy of rytvela (lipopolysaccharide + rytvela group, n=10); or (4) intraamniotic injection of Escherichia coli lipopolysaccharide in 2 mL saline and intraamniotic injections of 100 mg anakinra at time=0 hours and time=24 hours to test the anti-inflammatory efficacy of anakinra (lipopolysaccharide + anakinra group, n=12). Amniotic fluid was sampled at time 0, 24, and 48 hours (ie, at each intervention and at delivery). Fetal umbilical cord blood was collected at delivery for differential blood counts and chemical studies. Inflammation was characterized by the analysis of fetal tissue cytokine and chemokine levels using quantitative polymerase chain reaction, enzyme-linked inmmunosorbent assay, and histology. The primary study outcome of interest was the assessment of anakinra and rytvela brain-protective effects in the setting of Escherichia coli lipopolysaccharide-induced intrauterine inflammation. Secondary outcomes of interest were to assess protection from fetal and intrauterine (ie, amniotic fluid, chorioamnion) inflammation. RESULTS: Intraamniotic administration of lipopolysaccharide caused inflammation of the fetal lung, brain, and chorioamnionitis in preterm fetal sheep. Relative to treatment with saline only in the setting of lipopolysaccharide exposure, intraamniotic administration of both rytvela and anakinra both significantly prevented periventricular white matter injury, microglial activation, and histologic chorioamnionitis. Anakinra showed additional efficacy in inhibiting fetal lung myeloperoxidase activity, but its use was associated with metabolic acidaemia and reduced fetal plasma insulin-like growth factor-1 levels at delivery. CONCLUSION: Intraamniotic administration of rytvela or anakinra significantly inhibited fetal brain inflammation and chorioamnionitis in preterm fetal sheep exposed to intraamniotic lipopolysaccharide. In addition, anakinra treatment was associated with potential negative impacts on the developing fetus.
引用
- Takahashi Y, Takahashi T, Usuda H, et al. Pharmacological blockade of the interleukin-1 receptor suppressed Escherichia coli lipopolysaccharide-induced neuroinflammation in preterm fetal sheep. Am J Obstet Gynecol MFM. 2023. PMID: 37597799. doi:10.1016/j.ajogmf.2023.101124
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。